"DayTwo" Is investing millions in a laboratory for the genetic sequencing of intestinal bacteria

DayTwo, which provides personalized nutrition recommendations to balance blood sugar levels. Is investing $ 5 million in setting up the largest and most advanced laboratory in the world for the genetic sequencing of intestinal bacteria. This follows the significant increase in the number of customers in the past year, the company's preparations for entering the US market, and the signing of significant partnerships with leading health organizations around the world.
The company signed a 500-square-meter lease for 14 years at its sanatorium in Horowitz Park in Rehovot. The lab is expected to begin operations in February 2019 and is expected to run more than 100,000 samples a year. The location was chosen because of its geographic proximity to the Weizmann Institute, which leads the world-class microbial research field, which works closely with DayTwo.
Matching nutrition to microbial function is a new field in the science world. DayTwo was founded on the basis of groundbreaking research in the field of the Weizmann Institute, which found that the same food will cause different blood sugar reactions in different people. DayTwo has developed a system based on the science obtained, which allows to predict each person's individual sugar response to a large variety of foods. And to suggest nutrition recommendations tailored to each user's personal profile based on personal, clinical and genetic parameters of intestinal bacteria.
According to Lihi Segal, CEO and Founder of DayTwo, "The scope of the laboratory's activity is unprecedented in a world-class standard for the microbial sampling system, robotics and automatization of the process. As part of the expansion we are recruiting dozens of employees at various levels, in the life sciences and microbiology in particular. "
DayTwo was founded in 2015 by Marius Nacht (one of Check Point's founders and serial investor), together with Lihi Segal (CEO) and Yuval Ofek (Chairman), based on research by Prof. Eran Segal and Prof. Eran Elinav, The company raised $ 17 million, including Johnson & Johnson, Mayo Clinic, the French venture capital firm Seventh Partners, and other private investors including Omri Caspi, an NBA player and captain of Israel's national basketball team. In the company after experiencing the product and experiencing the positive change in person.
The company's first product, which provides a customized diet to balance blood sugar levels, is marketed in Israel and the US to the general public, with an emphasis on the diabetic population. In the US the product is distributed through health organizations, health insurance, employers, medical clinics and direct to the consumer.
The Rehovot St. complex includes a 6-story office building with a built-up area of ​​16,000 square meters and commercial space totaling 12,000 square meters. The complex is jointly owned by the new REIT Fund Ltd. (50%) with the company Yohanoff and the company Parshkovsky.